TP53 in hematological cancer: Low incidence of mutations with significant clinical relevance
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Inactivation of the wild-type p53 gene (TP53) by various genetic alterations is a major event in human tumorigenesis. More than 60% of human primary tumors exhibit a mutation in the p53 gene. Hematological malignancies present a rather low incidence of genetic alterations in this gene (10-20%). Nevertheless, epidemiological studies of the hematological malignancies indicate that the prognosis of patients with a mutation in the p53 gene is worse than those expressing the wild-type p53 protein. Correlations between drug resistance, altered apoptosis, and mutations in the p53 gene are found in hematological malignancies and leukemias. These issues, as well as the possibility of exploiting p53 and its various functions for new therapeutic strategies, are discussed in the present review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138 · cited 1×
“Mutant p53, on the other hand, cannot arrest cells at G1 and can deregulate apoptosis resulting in malignant transformation and proliferation [Lane, 1992; Levine, 1997; El-Deiry et al., 1994; Sigal and Rotter, 2000].”
BackgroundMdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Zhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521 · cited 2×
“It is not surprising, therefore, that a mutation in the CDKN2A gene disrupts both the Rb1 and p53 pathways [Pomerantz et al., 1998; Zhang et al., 1998; Drexler, 1998].”
BackgroundChristiansen, D. H., Andersen, M. K., & Pedersen-Bjergaard, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1405 · Cited by 308 · cited 1×
“However, in patients with AML or MDS previously treated with alkylating agents, the incidence of mutations increased to 27% [Christiansen et al., 2001].”
BackgroundZhu, Y.-M., Das-Gupta, E. P., & Russell, N. H. (1999) · Blood · doi:10.1182/blood.v94.2.733 · Cited by 118
Cited by
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
“The frequencies of reported TP53 mutations vary considerably between cancer types, ranging from ∼10% (for example, in haematopoietic malignancie”
BackgroundSelf-citationRivlin, N., Brosh, R., Oren, M., & Rotter, V. (2011) · Genes & Cancer · doi:10.1177/1947601911408889 · Cited by 1,033
Self-citationLoss of Tumor Suppressor Gene Function in Human Cancer: An Overview
Wang, L.-H., Wu, C.-F., Rajasekaran, N., & Shin, Y. K. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000495956 · Cited by 334
Kotler, E., Shani, O., Goldfeld, G., Lotan-Pompan, M., Tarcic, O., Gershoni, A., Hopf, T. A., Marks, D. S., Oren, M., & Segal, E. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.06.012 · Cited by 285
DNA Methylation Changes after 5-Aza-2′-Deoxycytidine Therapy in Patients with Leukemia
Yang, A. S., Doshi, K. D., Choi, S.-W., Mason, J. B., Mannari, R. K., Gharybian, V., Luna, R., Rashid, A., Shen, L., Estecio, M. R. H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2385 · Cited by 266
Metadata
- Authors
- Peller, S., & Rotter, V.
- Venue
- Human Mutation
- Publisher
- Hindawi Limited
- Published
- 2003-02-27
- Volume
- 21
- Issue
- 3
- Pages
- 277-284
- ISSN
- 1059-7794 (ISSN-L)
- 1098-1004
- OpenAlex
- W2084104960
- Cited by
- 142
- References
- 7
- FWCI
- 2.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TP53 in hematological cancer: Low incidence of mutations with significant clinical relevance. https://app.cochat.ai/papers/10.1002/humu.10190
- The paper
- Peller, S., & Rotter, V. (2003). TP53 in hematological cancer: Low incidence of mutations with significant clinical relevance. Human Mutation. https://doi.org/10.1002/humu.10190
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.